MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
1 . A method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling, said method comprising:
selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1 or Table 2, and a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the subject is human.
3 . The method of claim 1 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered.
4 . The method of claim 1 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered.
5 . (canceled)
6 . A method of activating the Wnt/β-catenin pathway in a subject comprising:
selecting a subject in need of Wnt/β-catenin pathway activating and
administering to the selected subject a compound selected from the group consisting of those set forth in Table 1 or Table 2, and a pharmaceutically acceptable salt thereof.
7 . The method of claim 6 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered.
8 . The method of claim 6 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered.